TEST:

Tempus xM

"Tempus AI, Inc...today announced xM for treatment response monitoring (TRM), a liquid biopsy assay intended to detect molecular response to immune-checkpoint inhibitor (ICI) therapy in advanced solid tumors. xM for TRM is the newest addition to Tempus’ growing portfolio of sensitive assays for monitoring molecular response and minimal residual disease (MRD)."

"Tempus AI,,,the adoption of AI to advance precision medicine and patient care, today announced that ten abstracts have been accepted for presentation at the 2025 American Society of Clinical Oncology (ASCO®) Annual Meeting. The event will take place May 30 – June 3 in Chicago, Illinois. Tempus will present its cutting-edge clinical findings and innovative technologies, highlighting the company’s use of AI-driven solutions to advance precision oncology."

WBL FCCDC achieved performance equivalent to conventional FCCDC, similar to WBL FCXM. The absence of adverse effects from the lysis step supports its integration into XM assays. Given its simplicity and maintained sensitivity, the WBL FCCDC protocol presents a viable alternative to conventional methods in histocompatibility laboratories.

It is an in silico test that assesses the immunological match between the recipient and the organ donor based on the analysis of the specificity of the antibodies present in the recipient's serum and the HLA typing of the organ donor. Each method has its own advantages and limitations, which are described below and need to be taken into account, considering their significant impact on clinical application in kidney transplantation.

This is a unique dataset that utilizes longitudinal tDNA TF as a TRM biomarker in advanced solid tumor patients treated with actionable TKIs. ctDNA TF monitoring added value in predicting rw outcomes beyond individual changes in actionable VAFs. These results should be further evaluated in prospective clinical datasets.

"Guardant Health filed a lawsuit...against rival cancer genomics firm Tempus AI, alleging that Tempus has infringed a handful of its patents relating to liquid biopsy sequencing methods...Guardant specifically cited Tempus' Tempus xF, Tempus xF+, and Tempus xM Monitor assays as examples, as well as the firm's recently developed minimal residual disease offering, Tempus xM MRD."

"Tempus...announced the company is scheduled to exhibit 16 abstracts at the 2024 American Society of Clinical Oncology (ASCO®) Annual Meeting, which convenes from May 31-June 4 in Chicago, Illinois. This year, Tempus is presenting its latest research, including new data from its minimal residual disease (MRD) assay, xM."

"Tempus...today announced the clinical launch of its minimal residual disease (MRD) test portfolio, including Tempus’ xM test and the xM (NeXT Personal Dx) test by Personalis. The portfolio features both a tumor-naïve assay and a tumor-informed assay that are designed to help detect residual disease or early cancer recurrence and monitor for immunotherapy treatment response, providing valuable insights to inform patient management strategies. The addition of both assays further complements Tempus’ comprehensive testing portfolio....xM was developed using the company’s multimodal database and advanced machine learning algorithms to accurately classify tumor fragments from non-tumor fragments, enhancing the precision of MRD calls."

"xM is a novel tumor-naïve MRD assay that demonstrated remarkable clinical longitudinal performance, and can accurately predict clinical recurrence on surveillance. xM ctDNA status was a strong prognostic biomarker to DFS and superior to standard of care CEA."

This model demonstrates that xM-guided treatment is cost-saving compared to imaging alone during 24 weeks of treatment. Future work will incorporate variable clinical uptake and long-term outcomes by expanding the time horizon and including treatment discontinuation due to toxicities and mortality.

xM is a novel tumor-uninformed assay that demonstrated remarkable performance to detect clinical recurrence at a LMT, and a clinically meaningful correlation with DFS. A larger clinical validation study including longitudinal analysis, correlation with ACT, and outcomes from the GALAXY study is currently underway.